Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Insulin sensitizers may slightly reduce hirsutism but are less effective than other treatments.

This study found that all four treatments—flutamide, finasteride, ketoconazole, and EE-CPA—significantly reduced hirsutism, but EE-CPA and flutamide appeared most effective, with varying effects on androgen levels and side-effect profiles.

This review found some evidence suggesting that spironolactone can effectively reduce hirsutism in women but did not support its use for treating acne vulgaris.

This study found that ethinylestradiol and high-dose cyproterone acetate significantly reduced hirsutism scores and were effective for treating acne and alopecia in women with hyperandrogenism.

This study found that ovarian suppression significantly reduced serum testosterone and androstenedione in women with polycystic ovarian syndrome and idiopathic hirsutism, with hair growth rates decreasing more in polycystic ovarian syndrome.

This study found that spironolactone, flutamide, and finasteride are similarly effective in reducing hair diameter and Ferriman-Gallwey scores in women with hirsutism over a 6-month treatment period.

In this study, cyproterone acetate at 2 mg daily was found to be as effective as higher doses in reducing hair growth for hirsute women over 12 months.

This study found that metformin treatment significantly improved hair growth in women with PCOS and hirsutism compared to a placebo.

This study found that shaving was the most helpful and commonly used temporary hair removal method among women with facial hirsutism.

This study observed that high-dose spironolactone frequently caused metrorrhagia in women with idiopathic hirsutism, leading the authors to suggest lower starting doses or additional hormonal therapy.

This review found that adding cyproterone acetate to estradiol showed a subjective improvement in hirsutism versus placebo, but comparisons with other therapies revealed no clinical differences.

This study found that in hirsute women, daily treatment with 200 mg spironolactone significantly reduced hair growth rates and hair shaft diameters on various body areas over 12 months.

This study found that women with symptoms of oligomenorrhoea and/or hirsutism are more likely to have polycystic ovaries and less favorable biochemical and clinical markers compared to asymptomatic women.

This study found that nafarelin treatment significantly reduced androgen levels and improved hirsutism symptoms in women, suggesting it may be useful for managing this condition.

This study found that both finasteride and flutamide effectively reduce hirsutism in women with polycystic ovary syndrome or idiopathic hirsutism, but flutamide was more effective.

This study concluded that finasteride, cyproterone acetate, and flutamide were similarly effective at reducing hirsutism in women, though they acted through different mechanisms.

This study found that finasteride effectively reduced hirsutism in women during 12 months of treatment, with some effects persisting in the majority after stopping the medication.

This review explores how androgens and growth hormone influence the development of terminal hairs and sebaceous glands, attributing variability in hirsutism and acne to differing genetic sensitivities to androgens, but reports no new experimental data.

This study found that treatment with leuprolide plus cyclic estrogen/progestin may lead to a faster and greater improvement in hirsutism compared to a standard oral contraceptive regimen.

In this study, women with idiopathic hirsutism who took finasteride for 9 months experienced a significant reduction in hirsutism scores compared to those receiving a placebo, with minimal side effects.

This study found that both cyproterone acetate and spironolactone effectively reduced hair diameter and plasma testosterone levels in hirsute women, with no significant differences between the two treatments.

This study reported that estrogen-progestin oral contraceptives, antiandrogens, and insulin sensitizers are more effective than placebo in treating hirsutism in women, with combination therapies generally proving superior to monotherapy.

This paper reviews causes of hirsutism in women and emphasizes the importance of identifying underlying conditions for risk assessment, though it reports no new clinical findings.

This article discusses the causes of hirsutism, identifying increased androgen production and heightened skin sensitivity, and provides no new clinical results.

This review discusses medical treatments for hirsutism, focusing on oral contraceptives and other therapies, but reports no new results; the authors emphasize the lack of evidence for insulin sensitizers in treating hirsutism alone.

This study found that serum 3 alpha-diol G levels in women with idiopathic hirsutism correlated well with their clinical response to treatment, suggesting its usefulness in evaluating treatment outcomes.

This study found that women with PCOS reported higher overall psychological distress, but there was no significant link between their perceived hirsutism and this distress.

In this study, treatment with the oral contraceptive containing 30 μg ethinyl oestradiol and 150 μg desogestrel significantly reduced androgen-dependent hair growth in hirsute women over one year.

This study found that Diane 35 combined with finasteride led to a greater reduction in hirsutism scores over 12 months compared to Diane 35 alone.

This study found that combining a GnRH agonist with a low-dose oral contraceptive was more effective in treating hirsutism than either agent alone and prevented hypoestrogenic side effects.